|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 39/155 | (2006.01) |
| A61P 31/14 | (2006.01) |
| (11) | Number of the document | 2667892 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12702153.3 |
| Date of filing the European patent application | 2012-01-26 | |
| (97) | Date of publication of the European application | 2013-12-04 |
| (45) | Date of publication and mention of the grant of the patent | 2019-03-27 |
| (46) | Date of publication of the claims translation | 2019-05-10 |
| (86) | Number | PCT/US2012/022762 |
| Date | 2012-01-26 |
| (87) | Number | WO 2012/103361 |
| Date | 2012-08-02 |
| (30) | Number | Date | Country code |
| 201161436355 P | 2011-01-26 | US |
| (72) |
DORMITZER, Philip, R., US
|
| (73) |
GlaxoSmithKline Biologicals SA,
Rue de l`Institut 89, 1330 Rixensart,
BE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | RSV imunizacijos režimas |
| RSV IMMUNIZATION REGIMEN |
| Payment date | Validity (years) | Amount | |
| 2022-12-20 | 12 | 289.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2023-07-04 |